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Objective: Endothelial dysfunction and decreased nitric oxide bioavailability may
explain why therapeutic angiogenesis and cell therapy have mostly failed in humans.
Building from previous large animal work, the Phase I Endothelial Modulation in
Angiogenic Therapy trial tested the hypothesis that L-arginine, a nitric oxide donor,
may be safe and effective in potentiating surgical angiogenesis in humans.
Methods: Patients with surgical triple-vessel coronary disease and a severely diffusely
diseased left anterior descending artery were randomized in 23 2 factorial fashion to
receive ten 200-mg injections of vascular endothelial growth factor-165 plasmid
DNA or placebo in the anterior myocardium along the proximal and mid-left anterior
descending arteries, plus oral L-arginine supplementation at a dose of 6 g per day or
placebo for 3 months. The distal left anterior descending artery and other coronary
arteries were grafted. End points included 3-month changes in myocardial perfusion
and contractility of the anterior myocardium, using 13N-ammonia positron emission to-
mography and echocardiography. Baseline scans were obtained 3 to 7 days postopera-
tively to delineate treatment effects from the effects of coronary artery bypass grafting.
Results: Patient (N5 19) characteristics were equivalent between groups. There was
no perioperative or late mortality. Patients who received the combination of vascular
endothelial growth factor and L-arginine had improved anterior wall perfusion on
positron emission tomography (P 5 .02), a trend toward smaller perfusion defects
(P5 .10), and better anterior wall contractility (P5 .02, Kruskal–Wallis) at 3 months
versus baseline. This was corroborated by a trend toward better disease perception at 3
months versus baseline on the Seattle Angina Questionnaire (score improvement of
47 6 35, combination treatment group; P 5 .1, Kruskal–Wallis).
Conclusion: To our knowledge, this is the first study to examine concomitant
substrate modification in patients undergoing new biosurgical therapies by using
vascular endothelial growth factor angiogenesis. The results suggest safety and
efficacy. Concomitant endothelial modulation with L-arginine not only has the
potential to make angiogenesis effective but also may have implications for cell
therapy trials.
P
atients with coronary artery disease (CAD) have markedly abnormal coronary
endothelial function and decreased nitric oxide (NO) bioavailability, particu-
larly when the CAD is severe and diffuse.1-4 We and others have shown that
angiogenesis depends on local NO levels,5-7 which may explain the discrepancy be-
tween successful animal studies and disappointing clinical trials of therapeutic
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Pangiogenesis.8 Furthermore, because paracrine angiogenesis
is a proposed mechanism for the effects of myocardial cell
therapy,9,10 it is possible that endothelial dysfunction and
decreased NO bioavailability may explain why cell therapy
trials have so far also led to disappointing results.
In animals, dietary supplementation of L-arginine, the
substrate for NO production, has been shown to reverse the
inhibition of angiogenesis that results from endothelial dys-
function.11-13 Because L-arginine has been shown to improve
coronary endothelial dysfunction in humans,14-17 we tested
the hypothesis that its use in patients undergoing angiogenic
therapy may make angiogenesis clinically more effective.
The Endothelial Modulation in Angiogenic Therapy
(EMAT) trial is a phase I 2 3 2 factorial, double-blind, dou-
ble placebo-controlled trial designed to evaluate the safety
and efficacy of intramyocardial vascular endothelial growth
factor (VEGF)-165 angiogenesis combined with oral L-argi-
nine supplementation in patients with severe diffuse CAD
undergoing coronary artery bypass grafting (CABG). The
primary end point of the trial was target territory myocardial
blood flow reserve quantified by positron emission tomogra-
phy (PET). Secondary end points were target territory con-
tractility on echocardiography, ischemic zone size on PET,
and clinical outcomes.
Materials and Methods
Patient Enrollment
The trial was approved by Health Canada, and research ethics board
approval was granted by the University of Ottawa. The trial was reg-
istered at ClinicalTrials.gov as NCT00134433. Enrollment took
place between August 12, 2004, and May 8, 2006. Patients were
at least 18 years of age, had symptomatic multivessel CAD, and
had been identified by at least 1 non-investigator cardiologist and
surgeon as having severe, diffuse CAD in the left anterior descend-
ing (LAD) artery (6 other coronary vessels) that could compromise
feasibility of surgical revascularization. Exclusion criteria included
pregnancy, lactation, or child-bearing potential; amenability for per-
cutaneous coronary intervention; akinesis of the anterior wall; left
ventricular ejection fraction (LVEF) less than 30%; recent (,1
month) ST-elevation myocardial infarction; chronic renal failure
(serum creatinine . 130 mmol/L); hepatic insufficiency (Child-
Pugh Class C or more); clinically significant valvular heart disease;
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CAD 5 coronary artery disease
EMAT 5 Endothelial Modulation in Angiogenic Therapy
LAD 5 left anterior descending
LITA 5 left internal thoracic artery
LVEF 5 left ventricular ejection fraction
NO 5 nitric oxide
PET 5 positron emission tomography
VEGF 5 vascular endothelial growth factorThe Journal of Thpersonal history of neoplasia; abnormal bowel cancer screening
questionnaire result; abnormal serum prostate specific antigen (if
male) or abnormal mammography (if female); family history of can-
cer in more than 1 first-degree relative; diabetic retinopathy; latent
herpes infection; schizophrenia; and claustrophobia.
Twenty-six eligible patients were referred among 282 patients
who underwent isolated primary CABG referred to the principal in-
vestigator (M.R.) during the enrollment period. Seven of these 26
eligible patients refused enrollment. One patient was operated by an-
other surgeon (F.R.) with the principal investigator in attendance
during the study procedures. Overall, 19 patients provided written
informed consent, were enrolled and randomized, and underwent
study procedures and follow-up.
Randomization
At operation, diffuse distal CAD of the target territory was confirmed
intraoperatively by a non-investigator surgeon before final confirma-
tion of eligibility. If eligible, each patient was double-randomized
to 1 of 4 groups: 1) placebo intramyocardial injections intraopera-
tively 1 placebo oral supplementation postoperatively; 2) VEGF
intramyocardial injections intraoperatively 1 placebo oral supple-
mentation postoperatively; 3) placebo intramyocardial injections in-
traoperatively 1 L-arginine oral supplementation postoperatively;
or 4) VEGF intramyocardial injections intraoperatively1 L-arginine
oral supplementation postoperatively. The randomization was double-
stratified by gender and according to the presence of LV dysfunction
(LVEF , 40%). Patients, their families, non-investigator clinicians,
and all members of the research team with the exception of the re-
search pharmacist were blinded to the treatment group assignment.
Surgical Technique and Postoperative Procedures
All operations were performed through a median sternotomy with the
use of cardiopulmonary bypass, aortic crossclamping, and antegrade
cold blood cardioplegia delivered at 20-minute intervals during car-
diac anoxia. Patients had the left internal thoracic artery (LITA)
grafted onto the LAD at a target site selected as being the most prox-
imal section of the LAD that was free of stenosis more than 50% dis-
tally. This site was determined by 2 surgeons (different from the
surgeon involved in patient screening/identification) from the combi-
nation of angiography and epicardial examination of the vessel, and
consisted of the distal LAD in all patients. At least 1 additional arte-
rial conduit (consisting of the right internal thoracic artery or left ra-
dial artery) was used to graft the target vessel from the circumflex or
right coronary distribution that subjectively subtended the largest
myocardial territory on coronary angiography. Greater saphenous
vein segments were used to complete the revascularization, includ-
ing the diagonal system if well developed and suitable for bypass.
Before release of the aortic crossclamp after completion of the last
distal anastomosis, 10 injections containing either good manufactur-
ing practice-grade, Health Canada-approved VEGF-165 plasmid
DNA (pVAX-1 VEGF165; manufactured at St Michael’s Hospital)
at a dose of 200 mg per injection for a total of 2 mg (total injected vol-
ume 1.8 mL), or physiologic saline (using an equal volume and num-
ber of injections) were performed 1 cm apart, in the underlying
anterior septum and myocardium along the proximal and mid-
LAD arteries (6 the initial distal LAD territory if proximal to the
anastomosis) cephalad to the LITA–distal LAD anastomotic site.
No injections were performed distal to the LITA–distal LADoracic and Cardiovascular Surgery c Volume 135, Number 4 763
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the downstream LAD was free of angiographically significant
(.50%) stenosis. The remainder of the operation was performed
as per routine. The study’s first patient, who had been randomized
to placebo injections and had diffuse disease of the posterior de-
scending artery in addition to diffuse LAD disease, had a LITA–dis-
tal LAD anastomosis and received inferior wall (placebo) injections
along the diseased posterior descending artery. After this initial pa-
tient, the protocol was amended to restrict it to injections along the
diffusely diseased proximal and mid-LAD arteries only.
Once in the cardiac surgical recovery unit, all patients were given
the contents of 1 orange-flavored sachet containing either 6 g of L-
arginine (Unither Pharmaceuticals, Silver Spring, Md) or placebo
reconstituted in 125 mL of water, administered via nasogastric
tube 4 hours after operation. On subsequent days throughout the
3-month study period, sachets were reconstituted in 250 mL of water
and taken daily by mouth.
Three to 5 days after CABG (7 days in 1 patient), patients under-
went nuclear rest/stress 13N-ammonia PET to determine baseline
myocardial perfusion and ischemic zone size, as well as transtho-
racic echocardiography to assess baseline anterior and global LV
function. Baseline imaging was performed during the early postop-
erative period rather than preoperatively to better separate the treat-
ment effects from the effects of CABG.18 Follow-up PET and
transthoracic echocardiography were repeated 3 months later at
the completion of the study. PET and echocardiography data were
interpreted by an experienced nuclear cardiologist and echocardiog-
rapher, respectively, who were both blinded to treatment and other
clinical and imaging data. Other aspects of postoperative care
were carried out as per routine.
Myocardial Perfusion
The primary end point of the study was differences in anterior myo-
cardial territory blood flow reserve quantified by PET. To this end,
patients underwent rest and dipyridamole stress 13N-ammonia dy-
namic PET imaging at baseline and at 3 months’ follow-up. Scans
were acquired on the ECAT ART (Siemens/CTI, Knoxville, Tenn)
PET scanner (12 3 10 seconds, 2 3 30 seconds, 1 3 60 seconds,
13 120 seconds, 13 240 seconds, 23 300 seconds, total5 20 min-
utes). Dynamic images were reconstructed using filtered back-pro-
jection with a 12-mm Hann window and automatically reoriented
into short-axis sections.19 Maximum activity profiles were obtained
from the uptake image, with a combination of planar and conical
sampling, and used to define the 3-dimensional shape of the LV myo-
cardium.20 The resulting 496 mid-myocardial coordinates were used
to resample the short-axis images into dynamic polar maps, produc-
ing regional time-activity curves for the myocardium. The arterial
blood time-activity curve was obtained from the average of 12
short-axis image regions (1.4 cm2 each), automatically placed in
the center of the cavity and base regions of the LV, and in the center
of the left atrium. A first-pass model was used to calculate the net re-
tention rate, with software corrections for wall thickness and motion.
Flow reserve was defined as the ratio of stress retention over rest
retention. Polar maps were used to calculate segmental LV values,
which were analyzed by using automated computer software to
provide independent, unbiased data. The anterior wall (4 subseg-
ments) was the target myocardial territory examined for evidence
of new angiogenesis through increased flow reserve. The mid-infe-
rior wall (2 subsegments), remote from intramyocardial injections,764 The Journal of Thoracic and Cardiovascular Surgery c Apwas used as a reference/control myocardial territory. The patient
who received inferior wall injections was excluded from all regional
myocardial perfusion analyses.
Left Ventricular Contractility
Dedicated study transthoracic echocardiograms were performed at
postoperative baseline and 3 months’ follow-up with the patient
placed in a left lateral decubitus position. Parasternal long- and
short-axis, and apical 2- and 4-chamber views were digitally ac-
quired and recorded for subsequent analysis. The left ventricle
was divided into 16 segments,21 and a regional wall motion score
was used (normal 5 1, hypokinetic 5 2, akinetic 5 3, dyskinetic
5 4). The anterior wall scores at postoperative baseline were sub-
tracted from the corresponding scores at 3 months’ follow-up to iso-
late the interval changes in anterior wall contractility. The patient
who received inferior wall injections was included in the contractil-
ity analyses because he presented severe diffuse LAD disease, had
a LITA–distal LAD anastomosis, and received placebo.
Clinical Outcomes
The secondary end points of the trial included major adverse cardiac
events, freedom from angina, angina class, and Seattle Angina
Questionnaire scores at 3 months versus preoperatively. All patients
were contacted by the investigators at 1, 2, 3, and 6 months; 1 year;
and yearly thereafter for a period of 15 years as per Health Canada
requirements. Clinical follow-up for more than 9 months is available
for all patients, and the mean follow-up was 16.7 6 6.8 months.
Power Calculations and Statistical Analyses
This phase I trial was designed to detect a myocardial blood flow dif-
ference of 0.25 mL/min/g between study groups on PET, at an a-
error level of 0.0125 and with a power of 0.80, with respect to the
combination of VEGF and L-arginine versus control groups (ie,
no active agent or either single agent). The 0.25 mL/min/g differ-
ence was chosen as within the reported myocardial flow and flow re-
serve responses to clinically beneficial treatments, which have been
reported as ranging from 12% to 54%, assuming a normal resting
flow of 1.0 mL/min/g.22 On this basis, the planned sample size
was 9 subjects per group 3 4 groups 5 36 subjects.
Discrete data are presented as numbers and percentages, and con-
tinuous data are presented as mean6 standard deviation or median.
Because of their normal distribution, determined by the Shapiro–
Wilk W test, PET flow reserve and defect size data were compared
by using analysis of variance (at baseline, follow-up, and their dif-
ference). All other data, including clinical and echocardiography
data, were compared by using a Kruskal–Wallis test. All reported
probability values were 2-tailed. Intercooled Stata version 9.2 (Stata,
College Station, Tex) was used for the statistical analyses.
Early Study Termination
On May 16, 2006, Health Canada released a public advisory stating
that ‘‘a recent study published in the Journal of the American Med-
ical Association in January of 2006 suggests that L-arginine may not
help improve heart and circulatory function following a first heart
attack and may be associated with an increased risk of death when
used after a heart attack.23 All L-arginine products must carry
a warning on their label that reflects the recent scientific information.
Health Canada has issued a stop-sale and recall on L-arginine-ril 2008
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For patients with heart disease who have not had a previous heart
attack, taking L-arginine is unlikely to present a risk and may pro-
vide benefits since L-arginine may help the body repair damage to
blood vessels in the heart.’’
As of May 16, 2006, 19 patients had been enrolled in the EMAT
trial. All patients had successfully undergone operation, and the last
3 patients were still taking postoperative daily oral L-arginine or pla-
cebo supplementation. We confirmed with Health Canada that the
advisory did not apply to patients in the EMAT trial, and a letter
was sent to the 3 patients who were still taking oral supplementation,
explaining the advisory and stressing that they were free to stop tak-
ing the L-arginine or placebo. All 3 patients chose to continue taking
the daily supplementation until the completion of the study. The tri-
al’s Data Safety and Monitoring Board reviewed all available data
and reported no related major adverse event. We decided to stop
enrollment for ethical reasons, with the study’s last patient con-
sequently having undergone operation on May 8, 2006, before the
advisory.
Results
Patient Characteristics and Perioperative Results
The results of the randomization schedule are available as
supplemental online material (Table E1). Baseline patient
characteristics were similar between groups (Table 1). No pa-
tient had left main coronary stenosis greater than 60%. The
extent of CABG surgery was the same in all treatment
groups, and coronary endarterectomy was avoided in all
patients. Intravenous tranexamic acid was administered to
all patients during the operation. There were no significant dif-
ferences between groups with regard to the number of grafts
(average 3.1 6 0.2), number of arterial conduits (average2.4 6 0.2), duration of cardiopulmonary bypass (average 80
6 21 minutes), or crossclamp time (average 536 17 minutes).
Patients received titrated intravenous nitroglycerin (0–2
mg/kg/min) and/or sodium nitroprusside (0–1 mg/kg/min)
during the first 24 postoperative hours if they were hyperten-
sive or if a radial artery graft had been performed. Dipyrida-
mole was not used at any time other than during PET imaging.
There was no early or late postoperative mortality. The
times to extubation (mean 11.76 7.0 hours; median 8 hours),
discharge from the intensive care unit (1.66 1.1 days; median
1 day), and discharge from hospital (10.46 8.7 days; median
8 days) were not different between groups. There was no re-
opening for bleeding, perioperative myocardial infarction
(by myocardial enzyme, electrocardiography, or echocardio-
graphic criteria), reintubation, or readmission to hospital.
Postoperatively, all patients were maintained on aspirin,
an angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker, a cholesterol-lowering agent, and a beta-
blocker. Three patients resumed their preoperative oral
nitrate medication (one in each of the VEGF 1 placebo
oral supplementation, placebo injections 1 L-arginine, and
VEGF1 L-arginine groups). All patients who received a ra-
dial artery graft were prescribed oral amlodipine 2.5 mg daily
for a period of 6 months.
Clinical Follow-up
At last follow-up, all patients were alive, showed Canadian
Cardiovascular Society angina class 1 or 2, and had no
myocardial infarction. There was no difference between
groups with respect to these outcomes. The second patientTABLE 1. Baseline patient characteristics
All patients
(n 5 19)
Placebo/placebo
(n 5 1)
VEGF/placebo
(n 5 7)
Placebo/L-arginine
(n 5 6)
VEGF/L-arginine
(n 5 5)
Age at surgery, y 59.1 6 8.6 66 58.3 6 9.7 60.0 6 8.7 57.8 6 8.9
Men/women, n 18/1 1/0 6/1 6/0 5/0
Body surface area, m2 2.1 6 0.2 2.3 2.1 6 0.2 2.1 6 0.1 2.2 6 0.2
Hypertension, n 14 (74%) 0 6 4 4
Tobacco use, n 3 (16%) 0 1 1 1
Hypercholesterolemia, n 16 (84%) 0 5 6 5
Diabetes, n 10 (53%) 1 4 3 2
CCS angina class
1 – – – – –
2 3 (16%) – 1 2 –
3 9 (47%) – 4 2 3
4 7 (37%) 1 2 2 2
Left ventricular grade*
1 12 (63%) – 4 4 4
2 4 (21%) – 2 2 –
3 3 (16%) 1 1 – 1
4 – – – – –
VEGF, Vascular endothelial growth factor; CCS, Canadian Cardiovascular Society. *Grade 1, LVEF $ 50%; grade 2, ejection fraction 40% to 49%; grade 3,
ejection fraction 30% to 39%; grade 4, ejection fraction , 30%.
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phy 3 months postoperatively for asymptomatic perfusion
abnormalities on PET. At angiography, grafts were found
to be widely patent, and the proximal and mid-LAD arteries,
which had been noted to be diffusely obliterated at operation,
appeared angiographically reconstituted. The patient, who af-
ter completion of the study was identified as having received
VEGF 1 L-arginine, has been free of angina since the oper-
ation and works full time. For all other patients in the EMAT
trial, we based the decision to perform repeat coronary angi-
ography on the presence of clinical symptoms, and no other
patient underwent repeat angiography at the last follow-up.
There was no difference in angina severity on the Seattle
Angina Questionnaire between groups. An improvement of
47 6 35 in disease perception scores at 3 months versus
preoperatively was observed in patients who received the
combination of VEGF 1 L-arginine, versus 17 6 29 during
the corresponding period in patients from other groups
(P 5 .1, Kruskal-Wallis).
Myocardial Perfusion
Figure 1 (top) displays the myocardial flow reserve in
a control myocardial territory (the mid-inferior wall) and in
the target myocardial territory (the anterior wall) on
13N-ammonia PET at baseline and follow-up, according to
treatment group. The patient who had placebo injections to
the inferior myocardium was excluded from these analyses.
There was no difference in flow reserve in the mid-inferior
myocardial territory at any time point between groups;
however, there was increased flow reserve at 3 months’
follow-up in the anterior wall in the group who received
VEGF 1 L-arginine (middle). This was observed both as
a higher flow reserve at follow-up and as a trend toward
a significantly greater difference in flow reserve at follow-
up from baseline. The increase in anterior wall flow reserve
from baseline to follow-up was also seen in the VEGF 1
L-arginine combination group when compared with patients
who received either or both placebos (P # .02; bottom).
Figure 2 depicts anterior wall stress perfusion abnormalities
at follow-up in a patient who had received VEGF1 placebo
versus a patient who had received VEGF 1 L-arginine.
Figure 3 displays the changes between baseline and fol-
low-up in the size of the rest and stress anterior myocardial
wall defects as measured by PET. In the VEGF1 L-arginine
combination group, both rest and stress anterior wall defects
decreased in size, whereas the reverse was observed in the
groups who received either or both placebos. This was
associated with a trend toward statistical significance (P5 .1).
Left Ventricular Contractility
LVEF increased by an average of 6.6% 6 5.3% from preop-
eratively to 3 months’ follow-up and by 1.6% 6 7.3% from
postoperative baseline to 3 months’ follow-up. There were no
significant differences in LVEF or LVEF change between766 The Journal of Thoracic and Cardiovascular Surgery c AprFigure 1. Myocardial flow reserve in a remote, noninjected
myocardial territory (mid-inferior wall) and in the injected
myocardial territory (the anterior wall) on 13N-ammonia PET at
baseline and 3-month follow-up. Treatment groups are denoted
as P (either or both placebos), V (VEGF), A (L-arginine), and C
(combination of VEGF 1 L-arginine). There was no difference in
flow reserve in the noninjected (mid-inferior) myocardial territory
at any time point between groups (top); however, there was
increased flow reserve at 3 months' follow-up in the injected (an-
terior) myocardium of patients who received VEGF 1 L-arginine
(middle). This was observed on flow reserve at follow-up and by
a trend toward a significantly greater difference from baseline
flow reserve. The increase in anterior myocardial flow reserve
in the VEGF 1 L-arginine combination group from baseline to
follow-up was also seen when this group was compared with
all other groups (bottom).il 2008
Ruel et al Cardiopulmonary Support and PhysiologyFigure 2. Three-dimensional left ven-
tricular representation of stress per-
fusion at 3 months' follow-up in
a patient who received VEGF along the
proximal and mid-LAD arteries 1 daily
placebo oral supplementation for 3
months (left) versus a patient who re-
ceived VEGF 1 daily L-arginine oral
supplementation for 3 months (right).
VEGF, Vascular endothelial growth fac-
tor; Ant, anterior wall; Inf, inferior
wall; Sep, septum.CS
Pgroups. In the anterior wall, the contractility at 3 months’ fol-
low-up versus postoperative baseline showed mild improve-
ment in 1 patient and no change in 4 patients who received
the VEGF 1 L-arginine combination, versus no change in
7 patients and a mild deterioration in 7 patients who received
either or both placebos (P5 .02, Kruskal–Wallis). There was
no significant difference between groups in the contractility
of other LV segments.
Discussion
The results of the EMAT trial suggest that the combination of
intramyocardial VEGF and L-arginine oral supplementation
for 3 months is safe and may potentiate angiogenesis.
Although the trial was stopped early, there is a suggestion
of efficacy for the primary end point of flow reserve in the
anterior myocardium, which was significantly higher in
patients who received VEGF and L-arginine versus those
who received either or both placebos. This was independent
from the effects of CABG and was corroborated with a trend
toward better Seattle Angina Questionnaire disease percep-
tion scores at 3 months versus baseline.
Figure 3. Changes in rest and stress defect size between baseline
and 3 months' follow-up, as measured by 13N-ammonia PET. The
defects decreased in size in the VEGF 1 L-arginine combination
group (C), whereas the reverse was observed in groups who
received either or both placebos (P).The Journal of ThoAnother finding of the EMAT trial is that VEGF and
L-arginine were not associated with major adverse events.
Although this is only suggestive of safety because the
number of patients was small, this is nevertheless important
considering the recent concern surrounding L-arginine use
in patients immediately after myocardial infarction;23 in light
of the present findings, it may be advisable to not hastily rule
out all future research using L-arginine in humans with CAD
because of that single trial. In fact, L-arginine has been shown
to be clinically safe, to have beneficial effects as a NO donor,
and to play a role in patients not immediately post-myocar-
dial infarction when administered in a carefully controlled
setting.
In this trial, we selected VEGF as an angiogenic agent
because it is well studied, safe, and clinically available, and
has a dependency on local NO availability that may exceed
that of other angiogenic agents, such as fibroblast growth
factor-2.24 VEGF therefore seemed well suited for our study
hypotheses. It is noteworthy that the LAD was bypassed in all
patients enrolled in this trial, distally as mandated by the
diffuse distal involvement, to ‘‘protect’’ them against the
possibility of ineffective angiogenesis. This shifted the focus
of the trial on regional myocardial perfusion differences
within the intervened myocardial territory rather than on
differences in clinical outcomes; therefore, the trial was
powered on a physiologic rather than a clinical end point.
Consequently, clinical and perfusion differences were
expectedly small, because all patients received multi-arterial,
complete revascularization. To convincingly establish the
clinical role of concomitant endothelial modulation therapy
in combination with new biosurgical therapies, subsequent
trials that evaluate their interaction will need to be adequately
powered to show a difference in clinical outcomes.
We do not believe that VEGF 1 L-arginine combination
therapy should be offered to patients with diffuse distal
CAD solely on the basis of the results of this trial. How-
ever, the present study provides data that are relevant andracic and Cardiovascular Surgery c Volume 135, Number 4 767
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and gene therapy have so far largely failed in patients,
and why clinical cell therapy may continue to lead to
disappointing results until host factors such as coronary
endothelial dysfunction, which is virtually always present
in patients for whom these new therapies are destined, are
concomitantly addressed.
Limitations
Serum L-arginine levels were not measured in this trial.
These may be quantified by high-performance liquid chroma-
tography, which is cumbersome and not routinely performed
clinically. Full compliance was reported by all patients,
which may have resulted from the severe nature of the pa-
tients’ disease, the trial’s close follow-up, and the procedural
involvement associated with the study. It is possible, how-
ever, that some patients may not have taken their L-arginine
every day despite having reported to have done so.
Coronary endothelial function was not measured in this
trial; however, L-arginine has been shown to positively affect
coronary endothelial function and myocardial NO availabil-
ity in large animals12,13 and humans.1,14 Because increased
myocardial rather than peripheral NO availability was the
target substrate modification in this trial, we did not perform
surrogate studies of flow-mediated dilation of the brachial
artery, which in addition are fraught with standardization
issues.25 Other limitations of the trial include early termina-
tion and resultant randomization imbalances from double-
stratification, and the lack of long-term follow-up, which
will be conducted annually for the next 15 years. It is also
important to note that this phase I trial was too small to fully
assess the safety of L-arginine, VEGF, or their interaction,
and that the observed absence of short- and mid-term
complications can be interpreted as being only suggestive
of safety.
Conclusions
Notwithstanding the above limitations, the phase I EMAT
trial 1) brings additional insight into the mechanisms of
action of new biosurgical therapies in humans by using
VEGF-based angiogenesis; 2) suggests the efficacy and po-
tential safety of L-arginine as 1 adjunct to make such thera-
pies more effective; and 3) provides preliminary data for
the design of larger clinical trials in angiogenesis and cell
therapy wherein patients could potentially benefit from con-
comitant modification of their myocardial substrate by using
L-arginine or other biologically supported and clinically safe
approaches.
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Discussion
Dr Todd K. Rosengart (Stony Brook, NY). The authors are to be
congratulated for translating solid experimental laboratory data
into a logical extension in clinical Unfortunately, as has been the
case on a number of occasions, the human condition has confounded
the efforts to reasonably and logically test some of your experimen-
tal hypotheses. I have a number of questions; but I’ll ask you 4,
which I’ll ask you one at a time for simplicity.
First, why did you not administer VEGF into an unrevascular-
ized territory so you could take advantage of a low baseline perfu-
sion level as opposed to administering VEGF into the LAD
territory? Obviously, this creates potential problems of artifact
because of your bypass grafts.
Dr Ruel. This is an excellent question and a point that we had to
resolve at the design level of the study. VEGF is a relatively poor
angiogenic factor, but it is intimately NO dependent, perhaps
more than fibroblast growth factor-2 and hepatocyte growth factor,
which are other cytokines that are potentially more robust. We also
chose VEGF first because it has been widely studied in humans, and
part of this comes from your work as well. We also chose VEGF
because it was available from our collaborators in addition to being
NO dependent.
On the other hand, we did not want to expose patients to the pos-
sibility of ineffective angiogenesis, which could have happened in
the VEGF and placebo groups. We thus protected our patients by
bypassing all their territories as well as we could, considering that
those patients all had diffuse LAD disease.
Furthermore, we had a precise measure of myocardial blood
flow. By performing the anterior myocardial bypass at the same tar-
get site in every patient, which was the distal LAD, we could focus
on the basal, mid, and early distal portions of the anterior wall to iso-
late the effect of VEGF.The Journal of ThoIn addition, the performance of baseline PET scanning, which
would be repeated at 3 months, early after the operation instead of
before the operation, accounted as best as possible for the confound-
ing effects of CABG.
Dr Rosengart. You mentioned in your article and presentation
that you used intraoperative validation or verification that the
LAD was suitable for your experimental protocol. Can you go
into a little bit more detail on that? Or conversely, did you attempt
to use any kind of strict angiographic guidelines to determine
whether you’d have a consistent cohort to study?
Dr Ruel. Those patients were screened on the basis of their
potential ungraftability. Several of them came from other centers
and were referred to us as ungraftable or likely ungraftable.
The intraoperative validation was informal. Initially, the patients
were screened and found to have a diffusely diseased LAD; in many
cases we thought that a LAD graft would perhaps not be construct-
ible. As many of us know, if you really put your mind to it, you can
basically graft anything with a lumen in it. So this is what we did,
and we bypassed the initial healthy portion of the LAD, which in
all patients corresponded to its most distal portion.
The intraoperative validation was done by a non-investigator car-
diac surgeon who confirmed that each patient had diffuse distal dis-
ease, but there were no specific radiologic measures to determine
eligibility for the trial. As you know, measures of coronary disease
diffuseness are controversial, and despite attempts in the literature
to develop those, they remain neither well accepted nor used.
DrRosengart. Again, in the same regard, you used baseline per-
fusion assay at days 3 to 5, or even in one case, I guess, day 7 post-
operatively. I’d be concerned that this introduced some variability.
Although you clearly show a difference between the experimental
and control groups, how do you know that the change in perfusion
is completely a VEGF effect as opposed to some collateralization
occurring because of the bypass?
Dr Ruel. You’re absolutely right. Again, your point deals with
the issues of doing this study in humans. We had few alternatives.
We thought that doing the baseline PET scanning preoperatively
would be less precise than doing what we did. However, there are
patients for whom undergoing a full PET scan 3 days after a bypass
operation is not ideal, especially those, as in this population, who
have diffuse coronary disease and may consequently have had
a slightly longer operation.
You’re absolutely right that VEGF has several effects. Angio-
genic cytokines are not only angiogenic but also have acute vascular
and other effects. For instance, VEGF results in local vasodilatation
and increased permeability. We did see some of these effects on
baseline PET scanning and tried to objectively and anatomically
account for them as best as possible.
As you know, the onset of action of VEGF and other angiogenic
cytokines is usually approximately 2 weeks, so we considered that
the first 5 days were relatively protected from most of the angiogenic
effects of the protein. It is possible that some patients may have been
better responders and their effects started before.
DrRosengart.Can you tell us a little bitmore about the toxicity, or
the purported toxicity, of L-arginine? Is this a real phenomenon or how
do we deal with that? If it is real, are there alternatives (which obviously
is NO or nitroglycerin) that would be suitable in a clinical arena?
Dr Ruel. I think a lot of researchers are disappointed by the bad
press recently attributed to L-arginine because of a single relativelyracic and Cardiovascular Surgery c Volume 135, Number 4 769
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CSPlimited scope trial published about a year ago. The trial dealt with
patients who had an acute ST elevation, had no revascularization,
and were randomized to receive L-arginine or not.
There may be other ways to modify endothelial function and NO
bioavailability. One way, for instance, may be to up-regulate770 The Journal of Thoracic and Cardiovascular Surgery c Apargininosuccinate synthase, which is a specific enzyme that derives
endothelial NO synthase from citrulline. So there are ways other
than L-arginine to make the myocardial substrate more amenable
to the new therapies that we want to see become effective one
day.Notice of Correction
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PTABLE E1. Endothelial Modulation in Angiogenic Therapy Trial Randomization Schedule
Patient No. (chronologic)
Placebo/placebo
(N 5 1)
VEGF/placebo
(N 5 7)
Placebo/L-arginine
(N 5 6)
VEGF/L-arginine
(N 5 5)
1 X
2 X
3 X
4 X
5 X
6 X
7 X
8 X
9 X
10 X
11 X
12 X
13 X
14 X
15 X
16 X
17 X
18 X
19 X
VEGF, Vascular endothelial growth factor.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 4 770.e1
